Showing results (11-20 of 34) with videos related to

Sort By:
Pageof 4
Internal Medicine Journal|November 20, 2024
Final results of the National Oncology Mentorship Program 2023 and its impact on burnout and professional fulfilmentUdit Nindra, Gowri Shivasabesan, Rhiannon Mellor, et al.
Exploration of Targeted Anti-Tumor Therapy|October 28, 2024
Evidence for the evolving role of neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancerThomas Hansen, Jonathon Hill, Gary Tincknell, et al.
Oncology|January 17, 2024
Variations in Patterns of Prescribing Durvalumab in Stage III Lung Cancer: A Survey of Australian Medical OncologistsUdit Nindra, Victoria Bray, Deme Karikios, et al.
JCO Oncology Practice|January 30, 2024
Evaluating Systemic Burnout in Medical Oncology Through a National Oncology Mentorship ProgramUdit Nindra, Gowri Shivasabesan, Rhiannon Mellor, et al.
Gastrointestinal Tumors|October 30, 2023
Real-World Outcomes of FLOT versus CROSS Regimens for Patients with Oesophagogastric CancersAdel Shahnam, Udit Nindra, Nicholas McNamee, et al.
Journal of the National Cancer Institute|August 4, 2023
Time to deterioration of patient-reported outcomes as a surrogate of overall survival: a meta-analysisAdel Shahnam, Udit Nindra, Jayesh Desai, et al.
Anticancer Research|April 27, 2024
Comparison of Prognostic Scores in Early Phase Clinical Trials: A 10-year Single Centre Australian ExperienceSarah Childs, Udit Nindra, Robert Yoon, et al.
Oncology|September 12, 2024
Social Characteristics of Culturally and Linguistically Diverse Cancer Patients Enrolled in Early Phase Clinical Trials in South Western SydneySarah Childs, Udit Nindra, Gowri Shivasabesan, et al.
Asia-Pacific Journal of Clinical Oncology|March 1, 2023
Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumabUdit Nindra, Adel Shahnam, Samuel Stevens, et al.
Thoracic Cancer|September 16, 2022
Elevated neutrophil-to-lymphocyte ratio (NLR) is associated with poorer progression-free survival in unresectable stage III NSCLC treated with consolidation durvalumabUdit Nindra, Adel Shahnam, Samuel Stevens, et al.
Pageof 4